John D Fissekis

Author PubWeight™ 6.01^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression.	Eur J Nucl Med Mol Imaging	2007	1.13
2	Synthesis and evaluation of 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil as a potential PET imaging agent for suicide gene expression.	J Nucl Med	2004	0.85
3	Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats.	Nucl Med Biol	2004	0.82
4	Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.	Cancer Res	2003	0.81
5	Synthesis of 2'-deoxy-2'-[18F]fluoro-5-bromo-1-beta-D-arabinofuranosyluracil ([18F]-FBAU) and 2'-deoxy-2'-[18F]fluoro-5-chloro-1-beta-D-arabinofuranosyl-uracil ([18F]-FCAU), and their biological evaluation as markers for gene expression.	Nucl Med Biol	2004	0.80
6	In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET.	Nucl Med Biol	2007	0.79
7	Biodistribution and PET imaging of [(18)F]-fluoroadenosine derivatives.	Nucl Med Biol	2007	0.79